# Accel-Rx Health Sciences Accelerator

> Accel-Rx Health Sciences Accelerator is a VC fund backing Biotechnology. See 14 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Vancouver, Canada
- Total investments: 14
- Last investment: Jul 2018
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/accel-rx
- X (Twitter): https://www.twitter.com/accel_rx
- Website: http://www.accel-rx.com

Accel-Rx Health Sciences Accelerator is a VC fund in Vancouver focused on Biotechnology and Health Care. Accel-Rx is a business accelerator focused on companies based in the health sciences sector.

## Contacts

5 contacts available for Accel-Rx Health Sciences Accelerator. Shizune tracks 1 team members at Accel-Rx Health Sciences Accelerator. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/accel-rx-health-sciences-accelerator?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 79% |
| Health Care | 8 | 57% |
| Pharmaceutical | 6 | 43% |
| Medical | 5 | 36% |
| Biopharma | 2 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Pre-Seed | 6 | 43% |
| Seed | 4 | 29% |
| Series A | 4 | 29% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Natalie Dakers | President and CEO | 2 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $7M | Series A | Jul 25, 2018 |  |
| Flosonics | Flosonics is a medical device company that focuses on developing non-invasive sensors to improve the management of critically ill patients. Flosonics's flagship smart-bandage product, the FloPatch, addresses unmet clinical needs of critically ill patients and the physicians, nurses, and paramedics who care for them in the ambulance,emergency department, operating room, and intensive care unit. | $5M | Seed | Jan 29, 2018 |  |
| Sepset Biosciences | Sepset Biosciences Inc., a CDRD portfolio company, in collaboration with Dr. Robert Hancock and Dr. Olga Pena, at the University of British Columbia, is developing a first in class diagnostic assay for the early and rapid diagnosis of sepsis. This unique diagnostic is based on the detection of a unique signature of sepsis based on the immuneresponse rather than the presences of a pathogen. |  | Pre-Seed | Jan 01, 2018 |  |
| Mesentech | Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions.Bone can be one of the most difficult organs to access and treat with medicines. It’s hardsurface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires administering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness.Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology. |  | Pre-Seed | Jan 01, 2018 |  |
| KalGene Pharmaceuticals | KalGene Pharmaceuticals, Inc. is a privately held company working in partnership with many of North America and Europe’s leading clinician-scientists and academic institutions. KalGene is focused on the development of targeted therapeutics and companion diagnostics. Its programs are aimed at improving clinical and survival outcomes through the useof personalized medicine. Personalized medicine seeks to predict which patients will respond to a particular therapy in advance of treatment. This prediction allows physicians to prescribe treatment according to an individual’s specific biological signature, or needs. |  | Series A | Nov 27, 2017 |  |
| SpecificiT Pharma | SpecificiT Pharma Inc., a privately held biopharmaceutical company focused on developing innovative personalized cancer immunotherapies.SpecificiT is developing cellular therapies for hematological cancers which to date, cannot be treated with chimeric antigen receptor modified T cells (CAR-T) therapies.SpecificiT’s unique approach iscentered on the use of Minor Histocompatability Antigens (“MiHAs”) which enable donor T-cells to be safely directed to eliminate cancer cells in a patient. |  | Seed | Sep 11, 2017 |  |
| Zucara Therapeutics | Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically blocksomatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar. | $525K | Pre-Seed | Nov 03, 2016 |  |
| Soundbite Medical Solutions | Soundbite Medical Solutions is a medical device company developing products in the field of vessel preparation for management and treatment. The company developing and commercializing a proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions(CTO's). It will target CTO’s in patients with peripheral artery disease (PAD) and coronary artery disease (CAD), disease states that affect over 12 million, and 8 million Americans, respectively.Founded in 2013 and is based in Montréal, Quebec, Canada. | $5M | Seed | Oct 31, 2016 |  |
| KisoJi Biotechnology | KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers. |  | Series A | Oct 12, 2016 |  |
| ImStar Therapeutics | ImStar Therapeutics is a biotech company that develops treatments for patients with amyotrophic lateral sclerosis. Its product pipeline is comprised of IMS-088, a small-molecule compound designed to address immune system activation pathway involved in neurodegeneration; and TDP-43 Associated NF-kB Activation Inhibitors.ImStar Therapeutics wasfounded in 2012 and is based in Vancouver, Canada. | $1.8M | Seed | Jun 08, 2016 |  |

10 of 14 investments shown.

## Co-investors
- [Amorchem](https://shizune.co/investors/profile/amorchem) — VC Fund, 2 deals together
- [Anges Quebec](https://shizune.co/investors/profile/anges-quebec) — VC Fund, 2 deals together
- [AQC Capital](https://shizune.co/investors/profile/anges-qu%C3%A9bec-capital) — VC Fund, 2 deals together
- [BDC Venture Capital](https://shizune.co/investors/profile/bdc-venture-capital) — VC Fund, 2 deals together
- [Genesys Capital](https://shizune.co/investors/profile/genesys-capital) — VC Fund, 2 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Everywhere Ventures](https://shizune.co/investors/profile/everywhere-ventures) — VC Fund

## FAQ

### What does Accel-Rx Health Sciences Accelerator invest in?

Accel-Rx Health Sciences Accelerator invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Pre-Seed and Seed stage. Most of the 14 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Accel-Rx Health Sciences Accelerator?

Public channels for Accel-Rx Health Sciences Accelerator include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Accel-Rx Health Sciences Accelerator?

The team at Accel-Rx Health Sciences Accelerator includes Natalie Dakers (President and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co